3rd ESTRO Forum 2015 S571 system were reviewed. IORT-related effects and early postoperative outcome were assessed. Results: Seventy eight patients (median age 67 years) underwent lumpectomy, sentinel lymph node biopsy, and concurrent IORT from march 2013 to march 2014. Ninety-five percent of patients had invasive ductal histology with a median tumor size of 1.5 cm. Conclusions: While a variety of APBI techniques are currently available for clinical use, our early Latin American operative experience with IORT shows it is well tolerated with low morbidity. The addition of WBI may be necessary in situations for positive residual margins or microscopic nodal disease in patients who do not undergo additional surgery. Implementation of IB impacts treatment planning and operating room use in a multidisciplinary breast cancer program. The safety profile, ease of administration, and reduced costs of IB favor its more widespread use in selected patients with early-stage breast cancer. Purpose/Objective: The Intrabeam system is a miniature accelerator emitting a 50 kV isotropic radiation. Its flat and surface applicators convert a spherical dose distribution into a flat one. This study aims at characterizing the dosimetric behaviour of these applicators for dermatologic applications. Materials and Methods: Dosimetric characterization was carried out in two steps. Firstly characterization was made in standard conditions for dermatologic applications, which is with the applicator directly on contact with the skin. Secondly, characterization was made in more clinical conditions, with obliquities and heterogeneities. Results: Behaviours of flat and surface applicators are different and have already been studied before. In standard conditions, dose rates and dose distribution results differ from previously published studies due to differences in the xray source design. The study showed that when contact between the applicator and the skin of the patient is not perfect there is a dose distribution spread on the edge of the irradiation field where the contact is not made. Dose loss due to lack of backscatter radiations is significant. By contrast, influence of a denser material behind the measurement point has no significant influence on the dose at this point. Thickness of tissue treated with flat and surface applicators is only a few millimetres, depending on the applicator's size.
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Purpose/Objective: The Intrabeam system is a miniature accelerator emitting a 50 kV isotropic radiation. Its flat and surface applicators convert a spherical dose distribution into a flat one. This study aims at characterizing the dosimetric behaviour of these applicators for dermatologic applications. Materials and Methods: Dosimetric characterization was carried out in two steps. Firstly characterization was made in standard conditions for dermatologic applications, which is with the applicator directly on contact with the skin. Secondly, characterization was made in more clinical conditions, with obliquities and heterogeneities. Results: Behaviours of flat and surface applicators are different and have already been studied before. In standard conditions, dose rates and dose distribution results differ from previously published studies due to differences in the xray source design. The study showed that when contact between the applicator and the skin of the patient is not perfect there is a dose distribution spread on the edge of the irradiation field where the contact is not made. Dose loss due to lack of backscatter radiations is significant. By contrast, influence of a denser material behind the measurement point has no significant influence on the dose at this point. Thickness of tissue treated with flat and surface applicators is only a few millimetres, depending on the applicator's size. Conclusions: The INTRABEAM® system with surface and flat applicators is a reliable way of treating superficial cutaneous malignancies as long as there is a good contact between the applicator and the skin. This work has been performed using the 50 kV X-ray source from the Intrabeam ® instrument (Carl Zeiss, Germany). EBT3 Gafchromic films were characterised within a water phantom and then used for in vivo dosimetry. Results: EBT3 Gafchromic films were found to be feasible for in vivo dosimetry. Measurements were performed in 10 patients resulting in measured doses from 9.04 to 17.71 Gy in the tumour bed and from 0.87 to 3.98 Gy on the skin. Conclusions: EBT3 Gafchromic films offered an accurate method for the measurement of both the tumour bed and skin.
PO-1059
Purpose/Objective: Head and neck squamous cell carcinoma (HNSCC) is frequently characterized by overexpression of anti-apoptotic Bcl-2 family members. Increased levels of these anti-apoptotic proteins has been associated with radioand chemoresistance and poor clinical outcome. Inhibition of anti-apoptotic Bcl-2 family members therefore represents an appealing strategy to overcome resistance to anticancer therapies. The aim of this study was to show enhanced radiation-induced tumor cell kill in HNSCC tumor cell lines in vitro, upon combined treatment with the pan-Bcl-2 inhibitor AT-101 and radiation. Additionally, we aimed to compare the effective in vitro concentrations with human serum levels of AT-101 obtained from a phase I/II trial, to substantiate therapeutic opportunities.
Materials and Methods:
In vitro, we examined the effect of AT-101 (kindly provided by Ascenta Therapeutics Inc.) radiation and the combination on apoptosis induction and clonogenic survival in two HNSCC cell lines that expressed the target proteins: UM-SCC-11B (derived from a primary tumor of the larynx) and VU-SCC-OE (derived from a primary tumor of the oral cavity). Apoptosis was determined by bisbenzimide staining to detect morphological nuclear changes and/or by propidium iodide staining and flow-cytometry analysis to quantify sub-diploid apoptotic nuclei. The type of interaction between AT-101 and radiation was evaluated by determining the Combination Index (CI) and isobolographic analysis. In addition, we assessed clonogenic survival upon combined treatment in the VU-SCC-OE cell line. In the clinical study, N07CRH, patients with locally advanced HNSCC, were enrolled in a two-arm trial design with standard radiotherapy/cisplatin treatment combined with concurrent dose-escalating oral AT-101 according to two different schedules, a 2-weeks daily schedule every 3 weeks, and a pulse-dose schedule on 3 consecutive days, every 3 weeks. Blood samples were collected and serum concentrations of AT-101 were determined by HPLC methods.
Results:
In vitro results showed that AT-101 (10-15 μM) enhances radiation(5Gy)-induced apoptosis with CI's ranging from 1.1 (additive) to 0.74 (synergistic). Clonogenic survival assays showed a radiosensitizing effect with a DEF 37 of 1.3 at concentrations of AT-101 that were markedly lower than used for apoptosis studies. Patients tolerated AT-101 well up to doses of 20 mg. Pharmacokinetic analyses of blood samples taken from the patients at time intervals from 30 minutes up to 24 hours after oral intake showed a dose-dependent increase in serum concentration with peak concentrations up to 300 -700 ng/ml (0.5 -1.2 μM) between 2 and 2.5 hours after intake. Conclusions: AT-101 is a competent enhancer of radiationinduced apoptosis in HNSCC in vitro. In addition, in vitro radiosensitization was observed at clinically achievable serum levels. These finding support further evaluation of the combination of AT-01 with radiation in Bcl-2-overexpressing tumors. Purpose/Objective: Radiation therapy is a primary treatment modality for prostate cancer. Over activation of the phosphoinositide 3-kinase (PI3K) pathway causes radioresistance increasing cell survival following radiation, resulting in treatment failure and disease recurrence. Downstream effects of PI3K increase HIF1-α concentrations resulting in high levels of hypoxia in PI3K activated prostate cancer cells. This study investigated the effect of PI3K inhibitor, GDC-0941, on the radiosensitisation of cell lines DU145 and 22Rv1 under hypoxic and normoxic conditions. Materials and Methods: GDC-0941 was combined with radiation treatment to assess the radiosensitisation effect in DU145 and 22Rv1 cell lines. GDC-0941 was also tested under hypoxic conditions to assess if radiosensitivity was maintained. Clonogenic assays were used to assess cell survival under the varied treatment conditions. Results: GDC-0941 was shown to enhance radiosensitivity in both 22Rv1 (2Gy: SER=1.7, p=0.038) and DU145 (2Gy: SER=2, p=0.0025). The radiosensitisation conferred was also significant under hypoxic conditions in 22Rv1 (2Gy: SER=2, p=0.0155) although non-significant in DU145 (2Gy: SER=1.1, p=0.1835). GDC-0941 showed comparable radiosensitisation under both normoxic and hypoxic conditions in both cell lines. Conclusions: GDC-0941 radiosensitised prostate cancer cells under hypoxic and normoxic conditions. ) is adopted for multiple strategies of cancer treatment encompassing classic chemotherapy on the one side as well as adjuvant treatment settings that combine chemotherapy with other treatment modalities like radiation therapy on the other. The molecular mechanism(s) by which Paclitaxel exerts radiosensitization of tumor cells is not understood in full detail. Moreover, the doses of Paclitaxel that are currently applied in the clinic often coincide with side effects of major severity. Finally, no stratification markers that allow for predicting the responsiveness of tumors towards treatment schedules involving Paclitaxel and radiotherapy are available thus far. Materials and Methods: Multiple concentrations of Paclitaxel were screened for respective effects on the viability and the proliferation of tumor cells. After identifying low nanomolar doses of Paclitaxel to impact tumor cell proliferation andviability in a hitherto highly neglected manner, a cohort of tumor cell lines was screened for individual differences in susceptibility towards equivalent doses of Paclitaxel, either administered alone or in combination with irradiation. Based on this screen, a search for new stratification markers was performed. Results: We show that Paclitaxel at lower nanomolar concentrations effectively sensitizes tumor cells towards ionizing radiation by facilitating high-grade aneuploidization. At such concentrations, Paclitaxel renders the ordinary, bipartite mode of cell division into a highly non-equational, mainly tripartite one thereby facilitating huge levels of aneuploidization and this is frequently followed by a distinct kind of apoptotic cell death. We show that this effect can be correlated with Paclitaxel-dependent radiosensitization of tumor cells since cell lines that are resistant to it are sensitized to lesser extends. We also provide evidence that both, Paclitaxel-dependent aneuploidization and -radiosensitization of tumor cells correlate with the expression levels of AURKA and TPX2, two proteins involved in mitotic spindle assembly, since a knockdown of TPX2 not only rescues the bipartite mode of cell division in the presence of Paclitaxel but also diminishes the radiosensitization effect that is achieved by Paclitaxel.
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